With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...
Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...
We recently published 10 Stocks Jim Cramer Talked About . Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...
All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...
More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback